Your browser doesn't support javascript.
Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China.
Qi, Geyao; Wang, Hao; Guo, Yufeng; Peng, Chi; Zhang, Chenxu; Chen, Ting; He, Jia; Jin, Zhichao.
  • Qi G; Department of Health Statistics, Naval Medical University, Shanghai, 200433, China.
  • Wang H; Department of Colorectal Surgery, ChangHai Hospital, Naval Medical University, Shanghai, 200433, China.
  • Guo Y; Department of Medical Administration, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
  • Peng C; Department of Health Statistics, Naval Medical University, Shanghai, 200433, China.
  • Zhang C; Department of Health Statistics, Naval Medical University, Shanghai, 200433, China.
  • Chen T; Department of Cardiology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
  • He J; Department of Health Statistics, Naval Medical University, Shanghai, 200433, China.
  • Jin Z; Department of Health Statistics, Naval Medical University, Shanghai, 200433, China. jinzhichao@smmu.edu.cn.
Clin Rheumatol ; 41(6): 1899-1910, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1850349
ABSTRACT

BACKGROUND:

The clinical outcomes of patients with rheumatic diseases infected with COVID-19 were inconsistent characteristics across regions and time periods. We need to revisit and sort out the clinical characteristics of these patients at the beginning of the global COVID-19 epidemic.

METHODS:

We collected data from confirmed COVID-19 patients from two military-run field hospitals and classified them into the rheumatic disease group and no rheumatic disease groups, and the latter was further distinguished by ARD and non-ARD. We compared the primary outcome, which we defined as mortality, and the secondary outcome, which we defined as the ICU occupancy rate, the duration of hospitalization and the duration of viral clearance, between the patients with and without rheumatic diseases after PSM. A study-level meta-analysis of four studies was conducted on the mortality of the COVID-19 patients with and without rheumatic diseases.

RESULTS:

A total of 4353 COVID-19 patients were included in our cohort study; 91 had rheumatic diseases. The mean age of the entire cohort was 59.37, and 2281 (52.40%) patients were female. The mortalities after PSM were 1.11% and 3.46% in the rheumatic diseases and no rheumatic disease groups, respectively. The ICU occupancy rates after PSM were 2.22% and 4.61% in the rheumatic diseases and no rheumatic disease groups. The duration of hospitalization and viral clearance in the rheumatic disease group were 15.97 and 43.69, respectively; moreover, the same parameters in the no rheumatic diseases after PSM were 15.48 and 45.48. No significant differences were found in either the primary or secondary outcomes. After excluding the gout cases, the results were still similar. However, there was a significant difference between the two groups upon meta-analysis (RR = 1.70, 95% CI 1.35-2.13).

CONCLUSIONS:

Rheumatic diseases seemed to aggravate the course of COVID-19 infection. However, the poor outcomes of COVID-19 seemed to be unassociated with rheumatic diseases undergoing an adequate medical intervention. KEY POINTS • We compared the outcomes and prognosis of COVID-19 patients in China at the beginning of the outbreak regarding the presence or absence of rheumatic disease patients and made some meaningful conclusions for future outbreaks of similar infectious diseases. • We compared similar recent studies from other countries and explored the changes and differences in patient outcomes associated with COVID-19 as it continued to spread worldwide during the year, providing clinical evidence to further explore the role rheumatic diseases play in COVID-19 patient outcomes. • We provided evidence for the treatment of relevant patients and made rationalized recommendations for treatment strategy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Long Covid Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Clin Rheumatol Year: 2022 Document Type: Article Affiliation country: S10067-022-06086-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Long Covid Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Clin Rheumatol Year: 2022 Document Type: Article Affiliation country: S10067-022-06086-2